vialaudit
The Roundup

affiliate disclosure · We earn affiliate commission on some vendor links. Audits, scores, and rankings are independent — vendors do not pay for placement and do not see drafts. read more →

peptide comparison · metabolic

Semaglutide vs Tirzepatide

Two compounds, mechanism by mechanism. Where they overlap, where they don't, and which vendors stock each.

§ 01

Mechanism

semaglutide

Semaglutide

OzempicWegovyRybelsus

GLP-1 receptor agonist. FDA-approved as Ozempic (T2D), Wegovy (obesity), and Rybelsus (oral T2D).

Full guide →
vs
tirzepatide

Tirzepatide

MounjaroZepbound

Dual GLP-1 / GIP receptor agonist. FDA-approved as Mounjaro (T2D) and Zepbound (obesity).

Full guide →
§ 02

Key facts

factSemaglutideTirzepatide
category
·metabolicmetabolic·
half-life
·~7 days~5 days·
research dosing
·Research literature cites 0.25–2.4 mg weekly subcutaneous.Research literature cites 2.5–15 mg weekly subcutaneous, escalated over 16+ weeks.·
trending
search demand
○82/10088/100●
vendors stocking
○12●
aliases
·Ozempic · Wegovy · RybelsusMounjaro · Zepbound·
§ 03

Use-case overlap

only semaglutide
  • cardiovascular risk reduction
both
  • weight loss
  • type 2 diabetes
only tirzepatide

none

§ 04

Where to buy

semaglutide
Semaglutide
1 verified vendor
Amino Asylum
See all vendors →
tirzepatide
Tirzepatide
2 verified vendors
Amino AsylumLimitless Life Nootropics
See all vendors →
§ 05

Sources

  1. [01]Once-Weekly Semaglutide in Adults with Overweight or Obesity (NEJM)· Semaglutide
  2. [02]Tirzepatide once weekly for the treatment of obesity (NEJM)· Tirzepatide
read next

Other peptide matchups

peptide matchupBPC-157 vs Retatrutidehealing × metabolicpeptide matchupBPC-157 vs Semaglutidehealing × metabolicpeptide matchupBPC-157 vs Tirzepatidehealing × metabolic
the roundup · monthly

Receipts in your inbox. Once a month.

New audits, expired coupons pruned, lab notes from vials still on the bench. No marketing. No lifestyle copy. Unsubscribe in one click.

14,200 subscribers· 0 sponsored items· 11 issues since launch